This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Administration for Strategic Preparedness and Response | |
|---|---|
| Name | Administration for Strategic Preparedness and Response |
| Formation | 2022 |
| Predecessor | Biomedical Advanced Research and Development Authority |
| Headquarters | Washington, D.C. |
| Chief1name | Secretary of Health and Human Services |
| Parent organization | United States Department of Health and Human Services |
Administration for Strategic Preparedness and Response is a federal agency within the United States Department of Health and Human Services established to lead national efforts in countering biological threats, chemical incidents, radiological emergencies, and pandemics. It consolidated functions from predecessors and coordinates with Centers for Disease Control and Prevention, Federal Emergency Management Agency, National Institutes of Health, and other federal partners to manage medical countermeasures, logistics, and surge capacity. The agency operates at the intersection of public health readiness and national security, engaging with international bodies such as the World Health Organization, North Atlantic Treaty Organization, and Pan American Health Organization.
The agency emerged from a reorganization following lessons from the 2001 anthrax attacks, the 2009 H1N1 pandemic, and the 2014 West African Ebola epidemic, inheriting responsibilities from entities including the Biomedical Advanced Research and Development Authority, the Office of the Assistant Secretary for Preparedness and Response, and components of the Health Resources and Services Administration. Its formation was shaped by legislation referencing the Public Health Service Act, debates in the United States Congress, and recommendations from panels including the National Academy of Medicine and the Government Accountability Office. High-profile events informing the agency’s evolution include the COVID-19 pandemic, policy reports by the National Security Council, and bipartisan hearings led by committees such as the United States Senate Committee on Health, Education, Labor, and Pensions and the United States House Committee on Energy and Commerce.
The agency’s mission draws on strategies articulated in documents by the Department of Homeland Security, the Office of the Director of National Intelligence, and the Defense Threat Reduction Agency to manage medical countermeasure development, procurement, and distribution. It coordinates with State of New York, Commonwealth of Puerto Rico, and local health departments, and partners with private sector firms including Pfizer, Moderna, Johnson & Johnson, GlaxoSmithKline, and Sanofi for vaccine and therapeutics manufacturing. The agency supports stockpiles such as the Strategic National Stockpile and collaborates with international procurement mechanisms like the Global Fund and Gavi, the Vaccine Alliance.
Organizational units mirror structures from the National Institutes of Health and the Centers for Disease Control and Prevention with directors overseeing divisions for research, logistics, policy, legal affairs, and operations. Leadership interacts with executive offices such as the Office of Management and Budget, the Office of the General Counsel (HHS), the White House, and Cabinet-level offices. Regional coordination involves entities like the Federal Emergency Management Agency Region IV, state health agencies of California Department of Public Health and Texas Department of State Health Services, and tribal health organizations including the Indian Health Service.
Major programs include replenishing and modernizing the Strategic National Stockpile, supporting advanced development programs similar to the Operation Warp Speed model, and funding initiatives aligned with the National Biodefense Strategy. It operates research consortia collaborating with institutions such as Harvard University, Johns Hopkins University, University of California, San Francisco, Massachusetts Institute of Technology, and Emory University. Public-private partnerships involve corporations like Merck & Co., AstraZeneca, Bristol Myers Squibb, and contractors including McKesson Corporation and DynCorp International. Initiatives extend to workforce development with academic partners like the Uniformed Services University of the Health Sciences and professional bodies such as the American Medical Association, Association of American Medical Colleges, and the National Association of County and City Health Officials.
Operational responses draw on playbooks used in responses to the H1N1 influenza pandemic, the Ebola virus epidemic in West Africa, and the COVID-19 pandemic, coordinating medical countermeasure distribution with logistics partners such as FedEx, United Parcel Service, and the Department of Defense logistics command. The agency conducts exercises with international allies including United Kingdom, Canada, Australia, Germany, and multilateral organizations like the European Centre for Disease Prevention and Control. It supports surveillance networks connecting to platforms from Centers for Disease Control and Prevention Epidemic Intelligence Service alumni, data-sharing arrangements with Palantir Technologies collaborators, and research collaborations with the Broad Institute.
Funding flows are set through appropriations from the United States Congress and oversight by the Government Accountability Office, with budget proposals coordinated with the Office of Management and Budget and approved in spending bills such as the Coronavirus Aid, Relief, and Economic Security Act and subsequent supplemental appropriations. The agency awards contracts and grants under procurement regulations administered by the General Services Administration and partners with philanthropic funders like the Bill & Melinda Gates Foundation and international financiers such as the World Bank on resilience loans and grants.
Critics have cited concerns raised in hearings before the United States Senate Committee on Homeland Security and Governmental Affairs and reports by the Government Accountability Office and Office of Inspector General (HHS), addressing issues including procurement transparency, contracting practices with firms like Emergent BioSolutions, supply chain vulnerabilities highlighted during the COVID-19 pandemic, and coordination challenges with state authorities including the New York State Department of Health. Debates in academic outlets at The Lancet, New England Journal of Medicine, and policy analyses by the Brookings Institution, RAND Corporation, and Center for Strategic and International Studies have critiqued preparedness priorities, stockpile management, and the balance between domestic production and global cooperation.